MedTrace Logo

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

NCT07389941 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-02-11

No results posted yet for this study

Summary

To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.

Conditions

  • Atrial Fibrillation (AF)

Interventions

DRUG

Semaglutide (SEMA)

Catheter ablation for AF plus semaglutide (up to 2.4 mg weekly)

Sponsors & Collaborators

  • University of Luebeck

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2029-04-30
Completion
2029-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07389941 on ClinicalTrials.gov